Project description DEENESFRITPL An innovative approach to colorectal cancer treatment In the last decade, colorectal cancer has become an alarmingly widespread type of cancer. Despite the significant improvements regarding its surgical treatment, many issues connected with mortality, recovery, recurrence rates and complications remain. The EU-funded CTI project is introducing a catheter for transcaecal ileostomy, an alternative technique to loop ileostomy to defunction low rectal anastomoses. The innovative solution makes the treatment of colorectal cancer patients safer, more efficient and effective as it decreases morbidity and mortality rates, diminishes hospital stay and "worried well" period and reduces operating time and faecal leakage. Show the project objective Hide the project objective Objective It is estimated that in 2018, 97,220 people will be diagnosed with colorectal cancer and that about 50,630 people will die from this disease; making treatment this cancer to be of growing importance nowadays. Despite improvements in the area of surgical treatment of the tumor, there are still many risk factors connected with mortality, recovery and reoccurrence rates, as well as complications (like anastomotic leakage). After having successfully launched an innovation that permits the transport of Ebola patients in 2014, Tecnoline (a medical company founded in 1992 in Modena, Italy) decided to invest into innovation development for the surgical treatment of colorectal cancer. Three years ago the team started developing a prototype of the Catheter for Transcaecal Ileostomy (CTI), an alternative technique to loop ileostomy to defunction low rectal anastomoses. Our company conducted a positive round of animal and clinical tests. The new invention is capable to decrease morbidity and mortality rates due to anastomotic leakage and surgery complications; diminish the hospital stay and ‘worried well’ by 50%; reduce the operating time by at least 50% and up to 99% leakage of feces. It also have a positive environmental impact since it replace the disposable plastic pouches and reduce energy use and other impacts connected with the patients stay in the hospitals. Finally, this invention has the potential to boost the company growth, translated into 8.91M€ of turnover (2025) and 40 new hires for the development period. Tecnoline was authorized by the Ethical Committee of Aragon (Spain) to implement CTI in a patient population in Aragon (18 patients). The solution has just passed through the experimental process and therefore reaches TRL7. Thus, it is the right moment to start preparing the CTI market readiness and roll-out to provide the medical sector with a unique solution that makes treatment of colorectal cancer patients safer, more efficient and effective. Fields of science social sciencessociologydemographymortalitymedical and health sciencesclinical medicinesurgerymedical and health scienceshealth sciencesinfectious diseasesRNA virusesebolamedical and health sciencesclinical medicineoncologycolorectal cancer Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) EIC-SMEInst-2018-2020 - SME instrument Call for proposal H2020-EIC-SMEInst-2018-2020 See other projects for this call Sub call H2020-SMEInst-2018-2020-1 Funding Scheme SME-1 - SME instrument phase 1 Coordinator TECNOLINE SPA Net EU contribution € 50 000,00 Address Via gelatti 11/a 41033 Concordia sulla secchia Italy See on map Region Nord-Est Emilia-Romagna Modena Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 21 429,00
